CareDx, Inc
CDNA
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $2.6B
$50.88
▲ +2.05%
P/E
23.65
Mkt Cap
$2.6B
52-Wk Range
$13.12–$53.67
52-Week Range
$13.12 - $53.67
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 281.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary dd-cfDNA technology with clinical validation across multiple organ types
- Integrated diagnostic and software platform creating switching costs and patient lock-in
- Strategic partnerships with Illumina for NGS distribution and technology development
- Established relationships with transplant centers and healthcare systems globally
- Comprehensive product portfolio addressing the entire transplant patient journey
Bear Case
2 risks
- High volatility (beta 2.4). Larger-than-normal price swings expected.
- Growth premium of 1.5x vs Life Sciences Tools peers. Reasonable for this growth rate.
Growth
Stable outlook
Expanding adoption of non-invasive dd-cfDNA monitoring in kidney, heart, and lung transplant markets
Value
Growth premium of 1.5x vs Life Sciences Tools peers. Reasonable for this growth rate.
Momentum
Hot
+131.8% over 3m
Quality
Excellent
High-growth business (34% revenue growth, 71% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying CDNA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
JUL 30, 2026
Reported EPS of $0.37 vs $0.23 consensus (+59.4% surprise). Revenue of $131.9M vs $114.0M expected (+15.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+59.4%
Revenue trend · last 8Q
—
+32%
+18%
-6%
+21%
+25%
+39%
+52%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$82.9M
$86.6M
$84.7M
$86.7M
$100.1M
$108.4M
$117.7M
$131.9M
Margins · last 8Q
Gross
0.0%
Operating
85.8%
Profit
83.8%
Wall Street consensus
3 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
—
Latest: BTIG · Aug 6, 2026
vs Industry
How CDNA stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related